Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR

International Journal of Cancer

Volumn 120, Issue 1, 2007, Pages 67-74

  Jacobs, Joannes F M ^a   Brasseur, Francis ^b   Hulsbergen van De Kaa, Christina A ^a   Van De Rakt, Mandy W M M ^c   Figdor, Carl G ^c   Adema, Gosse J ^c   Hoogerbrugge, Peter M ^a   Coulie, Pierre G ^d   De Vries, I Jolanda M ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d DE DUVE INSTITUTE   (Belgium)

Author keywords

Cancer; MAGE; NY ESO 1; Pediatrics; qPCR

Indexed keywords

MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 4; NY ESO 1 ANTIGEN;

ADOLESCENT; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CHILD; EWING SARCOMA; GAGE 1 GENE; GAGE 2 GENE; GAGE 8 GENE; GAGE 9 GENE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; LAGE 2 GENE; MAGE GENE; NEUROBLASTOMA; NEWBORN; OSTEOSARCOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; SOLID TUMOR;

ADOLESCENT; ADULT; ANTIGENS, NEOPLASM; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; INFANT, NEWBORN; MALE; MEMBRANE PROTEINS; NEOPLASM PROTEINS; NEOPLASMS; NEUROBLASTOMA; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA, MESSENGER; SARCOMA, EWING'S; TESTIS;

EID: 33845387727     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22118     Document Type: Article

References (57)

1. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T, Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64.
2. Boon T, Cerottini JC, Van den Eynde B, Van Der Bruggen P, Van Pel A. Tumor antigens recounized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
3. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001;411:380-4.
4. Velders MP, Markiewicz MA, Eiben GL, Kast WM, CD4+ T cell matters in tumor immunity. Int Rev Immunol 2003;22:113-40.
5. Kershaw MH, Trapani JA, Smyth MJ. Cytotoxic lymphocytes: redirecting the cell-mediated immune response for the therapy of cancer. Ther Immunol 1995;2:173-81.
6. Kalos M. Tumor antigen-specific T cells and cancer immunotherapy: current issues and future prospects. Vaccine 2003;21:781-6.
7. Sinkovics JG, Horvath JC. Vaccination against human cancers (review). Int J Oncol 2000;16:81-96.
8. van der Bruggen P, Traversari C, Chomez, P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991;254:1643-7.
9. De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C, Chomez P, De Backer O, et al. Structure, chromosomal localisation and expression of 12 genes of the MAGE family. Immunogenetics 1994;40:360-9.
10. Chomez P, De Backer O, Bertrand M, De Plaen L, Boon T, Lucas S. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res 2001;61:5544-51.
11. Van den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 1995;182:689-98.
12. De Backer O, Arden KC, Boretti M, Vantonune V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, et al. Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 1999;59:3157-65.
13. Lethe B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, De Plaen E, Boon T. LAGE-1, a new gene with tumor specificity. Int J Cancer 1998;76:903-8.
14. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old L.I. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997;94:1914-8.
15. Van den Eynde B, Van der Bruggen P. T-cell defined tumor antigens. Curr Opin Immunol 1997;9:684-93.
16. Chen Q, Jackson H, Parente P, Luke T, Rizkalla M, Tai JY, Zhu HC, Mifsud NA, Dimopoulos N, Masterman KA, Hopkins W, Goldie H, et al. Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. Proc Natl Acad Sci USA 2004;101:9363-8.
17. Davis ID, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W, Chen Q, Dimopoulos N, Luke T, Murphy R, Scou AM, Maraskovsky E et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004;101:10697-702.
18. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000;97:12198-203.
19. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded hy gene MAGE-3 and presented by HLA-A1. Int J Cancer 1999;80:219-30.
20. van Baren N, Bonnet MC, Dreno B, Khammari A, Dorval T, Piperno-Neumann S, Lienard D, Speiser D, Marchand M, Brichard VG, Escudier B, Negrier S et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 2005;23:9008-21.
21. Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dreno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with delectable metastatic melanoma. Int J Cancer 2005;117:596-604.
22. Marchand M, Punt CJ, Aamdal S, Escudier B, Kruiz WH, Keilholz U, Hakansson L, van Baren N, Humblet Y, Mulders P, Avril MF, Eggermont AM, et al. Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report. Eur J Cancer 2003;39:70-7.
23. Mackall CL, Fleisher TA, Brown MR, Andrich MP, Chen CC, Feuerstein IM, Horowitz ME, Magrath IT, Shad AT, Steinberg SM, Wexler LH, Gress RE, Age thymopoiesis and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
24. Heitger A, Greinix H, Mannhalter C, Mayerl D, Kern H, Eder J, Fink FM, Niederwieser D, Panzer-Grumayer ER. Requirement of residual thymus to restore normal T-cell subsets after human allogeneic bone marrow transplantation. Transplantation 2000;69:2366-73.
25. Raff T, van der Giet M, Endemann D, Wiederholt T, Paul M, Design and testing of β-actin primers for RT-PCR that do not co-amplify processed pseudogenes. Biotechniques 1997;23:456-60.
26. Zammatteo N, Lockman L, Brasseur F, De Plaen E, Lurquin C, Lobert PE, Hamels S, Boon T, Remacle J. DNA microarray to monitor the expression of MAGE-A genes. Clin Chem 2002;48:25-34.
27. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, Coplan K, Williamson B, Altorki N, Old LJ. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer 2001;92:856-60.
28. Chen YT, Stockert E, Chen Y, Garin-Chesa P, Rettig WJ, van der Bruggen P, Boon T, Old LJ. Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci USA 1994;91:1004-8.
29. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, Willimann T, Harder F, Heberer M, Spagnoli GC. Identification and intracellular location of MAGE-3 gene product. Cancer Res 1995;55:2236-9.
30. Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, Godelaine D. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer 2000;86:835-41.
31. Nickerson HJ, Matthay KK, Seeger RC, Brodeur GM, Shimada H, Perez C, Atkinson JB, Selch M, Gerbing RB, Stram DO, Lukens J. Favorable biology and outcome of stage IV-S neuroblastoma with supportive care or minimal therapy: a Children's Cancer Group study. J Clin Oncol 2000;18:477-86.
32. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005;5:615-25.
33. Bustin SA, Nolan T, Pitfalls of quantitative real-time reverse-transcription polymerase chain reaction. J Biomol Tech 2004;15:155-66.
34. Soling A, Schurr P, Berthold F. Expression and clinical relevance of NY-ESO-1, MAGE-1 and MAGE-3 in neuroblastoma. Anticancer Res 1999;19:2205-9.
35. Ishida H, Matsumura T, Salgaller ML, Ohmizono Y, Kadono Y, Sawada T. MAGE-1 and MAGE-3 or -6 expression in neuroblastomarelated pediatric solid tumors. Int J Cancer 1996;69:375-80.
36. Corrias MV, Scaruffi P, Occhino M, De Bernardi B, Tonini GP, Pistoia V. Expression of MAGE-1, MAGE-3 and MART-1 genes in neuroblasloma. Int J Cancer 1996;69:403-7.
37. Cheung IY, Barber D, Cheung NK. Detection of microscopic neuroblastoma in marrow by histology, immunocytology and reverse transcription-PCR of multiple molecular markers. Clin Cancer Res 1998;4:2801-5.
38. Rodolfo M, Luksch R, Stockert E, Chen YT, Collini P, Ranzani T, Lombardo C, Dalerba P, Rivoltini L, Arienti F, Fossati-Bellani F, Old LJ, et al. Antigen-specific immunity in neuroblastoma patients: antibody and T-cell recognition of NY-ESO-1 tumor antigen. Cancer Res 2003;63:6948-55.
39. Dalerba P, Frascella E, Macino B, Mandruzzato S, Zambon A, Rosolen A, Carli M, Ninfo V, Zanovello P, MAGE, BAGE and GAGE gene expression in human rhabdomyosarcomas. Int J Cancer 2001;93:85-90.
40. Sahin U, Tureci O, Chen YT, Seitz, G, Villena-Heinsen C, Old LJ, Pfreundschuh M. Expression of multiple cancer/test is (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategics. Int J Cancer 1998;78:387-9.
41. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line- and tumor-specilic genes with a CpG-rich promoter. Mol Cell Biol 1999;19:7327-35.
42. Dalerba P, Ricci A, Russo V, Rigatti D, Nicotra MR, Mottolese M, Bordignon C, Natali PG, Traversari C. High homogeneity of MAGE, BAGE, GAGE, tyrosinase and Melan-A/MART-1 gene expression in clusters of multiple simultaneous metastases of human melanoma: implications for protocol design of therapeutic antigen-specific vaccination strategies. Int J Cancer 1998;77:200-4.
43. Brasseur F, Rimoldi D, Lienard D, Lethe B, Carrel S, Arienti F, Suter L, Vanwijck R, Bourlond A, Humblet Y, Vacca A, Conese M, et al. Expression of MAGE genes in primary and metastalic cutaneous melanoma. Int J Cancer 1995;63:375-80.
44. Jung EJ, Kim MA, Lee HS, Yang HK, Lee YM, Lee BL, Kim WH. Expression of family A melanoma antigen in human gastric carcinoma. Anticancer Res 2005;25:2105-11.
45. Honda T, Tamura G, Waki T, Kawata S, Terashima M, Nishizuka S, Moloyama T. Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer 2004;90:838-43.
46. Li M, Yuan YH, Han Y, Liu YX, Yan L, Wang Y, Gu J. Expression profile of cancer-test is genes in 121 human colorectal cancer tissue and adjacent normal tissue. Clin Cancer Res 2005;11:1809-14.
47. Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stockert E, Gnjatic S, Williamson B, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004;64:2199-204.
48. Otte M, Zafrakas M, Riethdorf L, Pichlmeier U, Loning T, Janicke F, Pantel K. MAGE-A gene expression pattern in primary breast cancer. Cancer Res 2001;61:6682-7.
49. Yakirevich E, Sabo E, Lavie O, Mazareb S, Spagnoli GC, Resnick MB. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens in serous ovarian neoplasms. Clin Cancer Res 2003;9:6453-60.
50. Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, Remmel E, Noppen C, Schmid U, Ackermann D, Mihatsch MJ, Gasser T, et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer 2002;100:702-5.
51. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, Altorki NK. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res 2005;11:8055-62.
52. Melloni G, Ferreri AJ, Russo V, Gattinoni L, Arrigoni G, Ceresoli GL, Zannini P, Traversari C. Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncol Rep 2004;12:145-51.
53. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood 2005;105:3939-44.
54. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, Kolb D, Geller MD, Hassoun H, Kewalramani T, Comenzo RL, Coplan K, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7 and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun 2003;3:9.
55. Busam KJ, Iversen K, Berwick M, Spagnoli GC, Old LJ, Jungbluth AA. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. Mod Pathol 2000;13:459-65.
56. Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, Ohashi M, Hatakeyama K. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: implications for immunotherapy. Int J Cancer 2006;118:123-8.
57. Khong HT, Wang QJ, Rosenberg SA. Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J Immunother 2004;27:184-90.